



**Final Appraisal Recommendation**

Advice No: 2012 – July 2012

**Saxagliptin (Onglyza®) film-coated tablets**

**Limited submission by AstraZeneca UK Ltd**

**Recommendation of AWMSG**

**Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with insulin (with or without metformin) when this regimen alone with diet and exercise does not provide adequate glycaemic control.**

**Additional not:**

- AWMSG is of the opinion that saxagliptin (Onglyza®) may be appropriate for prescribing by all prescribers within NHS Wales for the above indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay/patient/carer perspective and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd
Date of first issue	July 2012
Last reviewed	September 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2012:  
Saxagliptin (Onglyza®) film-coated tablets. July 2012.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).